BACKGROUND AND OBJECTIVE: Hospitalization for exacerbation of COPD is associated with a high risk of mortality. A risk-prediction model using information easily obtained on admission could help to identify high-risk individuals. The CURB65 score was developed to predict mortality risk in community acquired pneumonia. A retrospective study found that this score was also associated with mortality in COPD exacerbations. We conducted a prospective study to assess the utility of the CURB65 score in acute COPD exacerbations. METHODS: Consecutive patients with physician diagnosed COPD exacerbations admitted to a public hospital during a 1-year period were studied prospectively. The CURB65 scores were calculated from information obtained at initial hospital presentation. CURB65 = one point each for Confusion, Urea > 7 mmol/L, Respiratory rate ≥ 30/min, low Blood pressure, age ≥ 65 years. RESULTS: 30-day mortality data were available for 249 of 252 patients. CURB65 scores on admission significantly predicted risk of death during the hospital admission and at 30 days. The 30-day mortality by score groups were: low risk (scores 0-1) 2.0% (2/98), moderate risk (score 2) 6.7% (6/90) and high risk (scores 3-5) 21.3% (13/61). CURB65 scores were not predictive of 1-year mortality. CONCLUSIONS: A simple 6-point score based on confusion, blood urea, respiratory rate, blood pressure and age can be used to stratify patients with COPD exacerbation into different management groups. The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia. Our findings suggest that CURB65 scores can help clinicians to assess patients with exacerbation of COPD.
BACKGROUND AND OBJECTIVE: Hospitalization for exacerbation of COPD is associated with a high risk of mortality. A risk-prediction model using information easily obtained on admission could help to identify high-risk individuals. The CURB65 score was developed to predict mortality risk in community acquired pneumonia. A retrospective study found that this score was also associated with mortality in COPD exacerbations. We conducted a prospective study to assess the utility of the CURB65 score in acute COPD exacerbations. METHODS: Consecutive patients with physician diagnosed COPD exacerbations admitted to a public hospital during a 1-year period were studied prospectively. The CURB65 scores were calculated from information obtained at initial hospital presentation. CURB65 = one point each for Confusion, Urea > 7 mmol/L, Respiratory rate ≥ 30/min, low Blood pressure, age ≥ 65 years. RESULTS: 30-day mortality data were available for 249 of 252 patients. CURB65 scores on admission significantly predicted risk of death during the hospital admission and at 30 days. The 30-day mortality by score groups were: low risk (scores 0-1) 2.0% (2/98), moderate risk (score 2) 6.7% (6/90) and high risk (scores 3-5) 21.3% (13/61). CURB65 scores were not predictive of 1-year mortality. CONCLUSIONS: A simple 6-point score based on confusion, blood urea, respiratory rate, blood pressure and age can be used to stratify patients with COPD exacerbation into different management groups. The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia. Our findings suggest that CURB65 scores can help clinicians to assess patients with exacerbation of COPD.
Authors: Ian G Stiell; Jeffrey J Perry; Catherine M Clement; Robert J Brison; Brian H Rowe; Shawn D Aaron; Andrew D McRae; Bjug Borgundvaag; Lisa A Calder; Alan J Forster; Jennifer Brinkhurst; George A Wells Journal: CMAJ Date: 2018-12-03 Impact factor: 8.262
Authors: Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera Journal: Lung India Date: 2013-07
Authors: Ian G Stiell; Catherine M Clement; Shawn D Aaron; Brian H Rowe; Jeffrey J Perry; Robert J Brison; Lisa A Calder; Eddy Lang; Bjug Borgundvaag; Alan J Forster; George A Wells Journal: CMAJ Date: 2014-02-18 Impact factor: 8.262
Authors: Gary E Weissman; Kuldeep N Yadav; Trishya Srinivasan; Stephanie Szymanski; Florylene Capulong; Vanessa Madden; Katherine R Courtright; Joanna L Hart; David A Asch; Sarah J Ratcliffe; Marilyn M Schapira; Scott D Halpern Journal: Med Decis Making Date: 2020-06-12 Impact factor: 2.583
Authors: Werner C Albrich; Frank Dusemund; Kristina Rüegger; Mirjam Christ-Crain; Werner Zimmerli; Thomas Bregenzer; Sarosh Irani; Ulrich Buergi; Barbara Reutlinger; Beat Mueller; Philipp Schuetz Journal: BMC Infect Dis Date: 2011-05-03 Impact factor: 3.090
Authors: Werner C Albrich; Kristina Rüegger; Frank Dusemund; Philipp Schuetz; Birsen Arici; Alexander Litke; Claudine A Blum; Rita Bossart; Katharina Regez; Ursula Schild; Merih Guglielmetti; Antoinette Conca; Petra Schäfer; Maria Schubert; Sabina de Geest; Barbara Reutlinger; Sarosh Irani; Ulrich Bürgi; Andreas Huber; Beat Müller Journal: Eur Respir J Date: 2013-01-24 Impact factor: 16.671